An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 33 人开始时间: 2016年10月26日最近更新: 2022年4月19日

试验速览

暂无简介。

•1. Male or female subjects, who experienced virologic failure during or after treatment with ABT 493/ABT-530 in an AbbVie HCV parent study. Subjects who have received virologic failure during or after receiving ombitasvir/paritaprevir/r + dasabuvir (3D), ombitasvir/paritaprevir/r (2D) in AbbVie HCV parent study may be enrolled at AbbVie's discretion.
•2. Subjects must be able to understand and adhere to the study visit schedule and all other protocol requirements.
•3. Cirrhotic Subjects must have compensated cirrhosis, (Child-Pugh score of = 6) at screening and no current or past evidence of Child-Pugh B or C Classification or no clinical history of liver decompensation, including ascites noted on physical exam, hepatic encephalopathy or esophageal variceal bleeding.
•4. Cirrhotic Subjects must have absence of hepatocellular carcinoma (HCC) as indicated by a negative ultrasound (US), computed tomography (CT) scan or magnetic resonance imaging (MRI) within 3 months prior to Screening or a negative US at Screening.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 35
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•1. History of severe, life-threatening or other clinically significant sensitivity to any study drug or drug component.
•2. Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or for 4 months after the last dose of study drug, or as directed per the local RBV label.
•3. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator, and failure in an AbbVie HCV parent study due to non-virologic reasons.
•4. Positive test result at Screening for hepatitis B surface antigen (HBsAg).
•5. Screening laboratory analyses showing creatinine clearance < 30 mg/dL.
•6. Discontinuation from the AbbVie HCV parent study for reasons other than virologic failure (e.g., non-adherence, lost to follow-up, and/or the occurrence of an adverse event).
•7. Receipt of any HCV treatment after failing the treatment regimen in the AbbVie HCV parent study.

发起方